Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling
Samuel J. Taylor, Samantha A. Dagger, Christine B.F. Thien, et al.
Blood (2012) Vol. 120, Iss. 19, pp. 4049-4057
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
Warren Fiskus, Sunil Sharma, Jun Qi, et al.
Molecular Cancer Therapeutics (2014) Vol. 13, Iss. 10, pp. 2315-2327
Open Access | Times Cited: 135
Molecular Pathways: Cbl Proteins in Tumorigenesis and Antitumor Immunity—Opportunities for Cancer Treatment
Mariya Liyasova, Ke Ma, Stanley Lipkowitz
Clinical Cancer Research (2014) Vol. 21, Iss. 8, pp. 1789-1794
Open Access | Times Cited: 96
Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede, Margaret Nieborowska-Skorska, Katherine Sullivan-Reed, et al.
Blood (2018) Vol. 132, Iss. 1, pp. 67-77
Open Access | Times Cited: 67
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere, et al.
JCI Insight (2016) Vol. 1, Iss. 3
Open Access | Times Cited: 64
UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
Deborah DeRyckere, Alisa B. Lee‐Sherick, Madeline G. Huey, et al.
Clinical Cancer Research (2016) Vol. 23, Iss. 6, pp. 1481-1492
Open Access | Times Cited: 64
Potential targeting of FLT3 acute myeloid leukemia
Alexander J. Ambinder, Mark J. Levis
Haematologica (2020) Vol. 106, Iss. 3, pp. 671-681
Open Access | Times Cited: 61
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO
Susumu Goyama, Janet Schibler, Anjelika Gasilina, et al.
Leukemia (2015) Vol. 30, Iss. 3, pp. 728-739
Open Access | Times Cited: 57
Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia
Bai‐Liang He, Xiangguo Shi, Cheuk Him Man, et al.
Blood (2014) Vol. 123, Iss. 16, pp. 2518-2529
Open Access | Times Cited: 56
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies
Kaosheng Lv, Jing Jiang, Ryan Donaghy, et al.
Genes & Development (2017) Vol. 31, Iss. 10, pp. 1007-1023
Open Access | Times Cited: 56
LAMTOR2 regulates dendritic cell homeostasis through FLT3-dependent mTOR signalling
Julia M. Scheffler, Florian Sparber, Christoph H. Tripp, et al.
Nature Communications (2014) Vol. 5, Iss. 1
Open Access | Times Cited: 42
Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling
Alexia Conte, Sara Sigismund
Progress in molecular biology and translational science (2016), pp. 225-276
Closed Access | Times Cited: 41
Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib
Samuel J. Taylor, Johanna M. Duyvestyn, Samantha A. Dagger, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 402
Closed Access | Times Cited: 41
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1
Roger Belizaire, Sebastian Koochaki, Namrata D. Udeshi, et al.
Blood (2021) Vol. 137, Iss. 16, pp. 2209-2220
Open Access | Times Cited: 30
Phase 1 study of Azacitidine in Combination with Quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN
Guillermo Montalban‐Bravo, Elias Jabbour, Kelly S. Chien, et al.
Leukemia Research (2024) Vol. 142, pp. 107518-107518
Closed Access | Times Cited: 4
Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors
Andrew L. McIver, Weihe Zhang, Qingyang Liu, et al.
ChemMedChem (2016) Vol. 12, Iss. 3, pp. 207-213
Open Access | Times Cited: 33
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Jorge E. Cortés
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
A Comprehensive Review of Pacritinib in Myelofibrosis
Srđan Verstovšek, Rami S. Komrokji
Future Oncology (2015) Vol. 11, Iss. 20, pp. 2819-2830
Open Access | Times Cited: 32
PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
Christina‐Nefeli Kontandreopoulou, Panagiotis Diamantopoulos, Despina Tiblalexi, et al.
Blood Advances (2021) Vol. 5, Iss. 22, pp. 4794-4805
Open Access | Times Cited: 23
Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy
Wei An, Scott Nadeau, Bhopal Mohapatra, et al.
Oncotarget (2015) Vol. 6, Iss. 12, pp. 10498-10509
Open Access | Times Cited: 25
Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group
Jichen Zhao, Dehui� Zhang, Weihe Zhang, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 22, pp. 10242-10254
Closed Access | Times Cited: 25
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
Isabella Faraoni, Manuela Giansanti, Maria Teresa Voso, et al.
Biochemical Pharmacology (2019) Vol. 167, pp. 133-148
Closed Access | Times Cited: 24
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update
Bei Hu, Praveen Vikas, Mohamad Mohty, et al.
Expert Review of Hematology (2013) Vol. 7, Iss. 2, pp. 301-315
Closed Access | Times Cited: 17
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice
Samuel J. Taylor, Christine B.F. Thien, Samantha A. Dagger, et al.
Experimental Hematology (2014) Vol. 43, Iss. 3, pp. 191-206.e1
Open Access | Times Cited: 16
Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice
Anna Staffas, Laleh S. Arabanian, Shuang Wei, et al.
Oncogene (2016) Vol. 36, Iss. 11, pp. 1516-1524
Open Access | Times Cited: 16
The Phosphatases STS1 and STS2 Regulate Hematopoietic Stem and Progenitor Cell Fitness
Jing Zhang, Olesya Vakhrusheva, Srinivasa Rao Bandi, et al.
Stem Cell Reports (2015) Vol. 5, Iss. 4, pp. 633-646
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top